E. coli L-asparaginase in the treatment of leukemia and solid tumors in 131 children.
D000293:Adolescent; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001215:Asparaginase / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D002493:Central Nervous System Diseases / Q000150:complications; D002648:Child; D002675:Child, Preschool; D003888:Desensitization, Immunologic; D004342:Drug Hypersensitivity / Q000209:etiology; D004926:Escherichia coli / Q000201:enzymology; D005260:Female; D005334:Fever / Q000139:chemically induced; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D007223:Infant; D007273:Injections, Intramuscular; D007278:Injections, Spinal; D007938:Leukemia / Q000150:complications / Q000188:drug therapy*; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D007958:Leukocyte Count; D008111:Liver Function Tests; D008223:Lymphoma / Q000188:drug therapy; D008297:Male; D013997:Time Factors
D000970:Antineoplastic Agents; D001215:Asparaginase